|
|||||
|
|
Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non‐valvular atrial fibrillation |
|
| Authors: | Y. Lu PharmD MS BCPS R. Branstad PharmD BCPS R. M. Karim MD FHRS R. W. Asinger MD FACC |
| Affiliation: | 1. Hennepin County Medical Center, , Minneapolis, MN, USA;2. University of Minnesota, , Minneapolis, MN, USA;3. Electrophysiology Laboratory, Hennepin County Medical Center, , Minneapolis, MN, USA;4. Cardiac Rehabilitation Laboratory, Hennepin County Medical Center, , Minneapolis, MN, USA |
| Abstract: | |
| Keywords: | anticoagulant apixaban atrial fibrillation dabigatran drug information medication prescribing practices new oral anticoagulant rivaroxaban |